Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)

Immunoglobulin G (IgG) replacement therapy is a standard treatment for patients with primary immunodeficiency diseases (PIDs). Hizentra®, a 20% human subcutaneous IgG (SCIG), is approved for biweekly administration for PIDs. The aim of the multicenter IBIS study was to prospectively investigate the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Immunol
Main Authors: Vultaggio, Alessandra, Azzari, Chiara, Ricci, Silvia, Martire, Baldassarre, Palladino, Valentina, Gallo, Vera, Pecoraro, Antonio, Pignata, Claudio, Spadaro, Giuseppe, Graziani, Simona, Moschese, Viviana, Trizzino, Antonino, Boggia, Giorgio Maria, Matucci, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6061090/
https://ncbi.nlm.nih.gov/pubmed/29951948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-018-0528-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados